Abstract: The abnormal activation of phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway takes place in a variety of tumors. This pathway, which is an important target for the development of anti-tumor drugs, mediates the regulation of tumor cell proliferation, differentiation and apoptosis. This article summarized the PI3K/AKT/mTOR pathway inhibitors used in clinical practice and undergoing clinical trials, and also reviewed the combination strategy of several pathway inhibitors with other targeted drugs, which may offer personalized approach for the treatment of different breast cancer subtypes.

Key words: PI3K/AKT/mTOR pathway, Inhibitor, Breast cancer, Combination therapy